Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 163

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study

Open access
Karol, Seth E, Alexander, Thomas B, Budhraja, Amit, Pounds, Stanley B, Canavera, Kristin, Wang, Lei, Wolf, Joshua, Klco, Jeffery M, Mead, Paul E, Das Gupta, Soumyasri, Kim, Su Y, Salem, Ahmed Hamed, Palenski, Tammy, Lacayo, Norman J, Pui, Ching-Hon, Opferman, Joseph T, Rubnitz, Jeffrey E · 2020 · The Lancet Oncology

Abstract

Summary Background: Outcomes for children with relapsed or refractory acute myeloid leukemia (AML) remain poor. The BCL-2 inhibitor venetoclax has shown promising activity in combination with hypomethylating agents and low-dose cytarabine in older, unfit adults with newly diagnosed AML. The aims of the present study were to determine the safety and explore the activity of venetoclax with standard and high-dose chemotherapy in pediatric patients with relapsed AML. Methods: Patients with relapsed or refractory AML or acute leukemia of ambiguous lineage who were 2–22 years old and who had adequate organ function and performance status were eligible. We tested the safety and activity of venetoclax (240 or 360mg/m2/day orally for 28 days) in combination with cytarabine (100mg/m2/dose IV every 12 hours for 20 doses or 1000mg/m2/dose IV every 12 hours for 8 doses) with or without idarubicin (12mg/m2 IV). The primary endpoint was the recommended phase 2 dose (RP2D) of venetoclax plus chemotherapy and the secondary endpoint was the proportion of patients treated at the RP2D who achieved complete remission (CR) or complete remission with incomplete count recovery (CRi). Analyses were done per protocol. The study was at ClinicalTrials.gov (NCT03194932). The primary objective has been reached and the study is enrolling to address exploratory objectives. Findings: Thirty-eight patients were enrolled from July 1, 2017 to July 2, 2019, with a median follow-up of 7.1 months (IQR 5.1–11.2). The RP2D of venetoclax was 360mg/m2 (600mg max) combined with cytarabine (1000mg/m2/dose for 8 doses) with or without idarubicin (12mg/m2 as a single dose). Overall responses were observed in 24 (69%) of 35 evaluable patients, including 16 CR (11 MRD negative), 4 CRi (2 MRD negative), and 4 PR. Among the 20 patients treated at the RP2D 14 (70%) achieved CR or CRi and 16 (80%) CR/CRi/PR. The most common grade 3–4 adverse events were febrile neutropenia (25 patients), bloodstream infections (6 patients), and invasive fungal infections (6 patients). Treatment-related death occurred in only one patient. Interpretation: The safety and activity of venetoclax plus chemotherapy in patients with heavily pre-treated, relapsed and refractory AML suggests that this combination should be tested in newly diagnosed patients with high-risk AML. Funding: ALSAC, AbbVie, Gateway for Cancer Research, National Institutes of Health CA21765

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30060-7

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 163

Metadata

Authors
Karol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., Kim, S. Y., Salem, A. H., Palenski, T., Lacayo, N. J., Pui, C.-H., Opferman, J. T., & Rubnitz, J. E.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2020-04
Volume
21
Issue
4
Pages
551-560
ISSN
1470-2045 (ISSN-L)
OpenAlex
W3011638072
Cited by
163
References
3
FWCI
13.91
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. https://app.cochat.ai/papers/10.1016/s1470-2045(20)30060-7
The paper
Karol, S. E., Alexander, T. B., Budhraja, A., Pounds, S. B., Canavera, K., Wang, L., Wolf, J., Klco, J. M., Mead, P. E., Das Gupta, S., Kim, S. Y., Salem, A. H., Palenski, T., Lacayo, N. J., Pui, C.-H., Opferman, J. T., & Rubnitz, J. E. (2020). Venetoclax in combination with cytarabine with or without idarubicin in children with relapsed or refractory acute myeloid leukaemia: a phase 1, dose-escalation study. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(20)30060-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.